Levosimendan Amdipharm

Levosimendan, the active ingredient in Levosimendan Amdipharm, is a calcium sensitizer / inodilator presented as an injectable solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Levosimendan Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of severe cardiac conditions where enhanced contractility and vasodilation are required. - Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion. - Cardiogenic shock: supports systemic blood pressure and organ perfusion. - Pre‑transplant stabilization: provides hemodynamic support while awaiting definitive therapy.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: reduction in systolic blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Arrhythmia: non‑sustained ventricular ectopy.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachyarrhythmias: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: worsening respiratory status. - Liver enzyme elevation: transient transaminase rise.

Levosimendan requires careful monitoring and specific safety measures before and during administration. - Blood pressure monitoring: check for hypotension before infusion. - Cardiac rhythm surveillance: observe for arrhythmias during therapy. - Dose adjustment: consider renal or hepatic impairment when determining infusion rate. - Concomitant vasodilators: use cautiously with nitrates or other blood‑pressure‑lowering agents. - Severe hypotension: avoid in patients with baseline systolic pressure <90 mmHg. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines that affect cardiovascular function or drug metabolism.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase levosimendan exposure. - Other inotropes or calcium sensitizers: risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Nitrates or other vasodilators: additive hypotensive effect. - Beta‑blockers: may blunt desired inotropic response. - Diuretics: monitor electrolyte balance and volume status. - Anticoagulants: watch for bleeding if hypotension occurs. - Anti‑arrhythmic agents: assess for synergistic rhythm disturbances.